A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2B multicenter, randomized, double-blind, placebo-controlled, parallel group
dose finding study to evaluate the safety, tolerability and efficacy of PQ912, an inhibitor
of the glutaminyl cyclase enzyme, in 250 subjects with mild cognitive impairment and mild
dementia due to Alzheimer 's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Vivoryon Therapeutics AG Vivoryon Therapeutics N.V.
Collaborators:
Nordic Bioscience A/S VU University Medical Center